1 / 10

PrEP Pre-Exposure Prophylaxis

PrEP Pre-Exposure Prophylaxis. Lori Miller AVAC: Global Advocacy for HIV Prevention 22 MAY 2010. Experimental HIV prevention strategy that would use antiretrovirals (ARVs) to reduce the risk of HIV infection in HIV-negative people

nash-harper
Download Presentation

PrEP Pre-Exposure Prophylaxis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PrEPPre-Exposure Prophylaxis Lori MillerAVAC: Global Advocacy for HIV Prevention22 MAY 2010

  2. Experimental HIV prevention strategy that would use antiretrovirals (ARVs) to reduce the risk of HIV infection in HIV-negative people In this strategy, people would take a single drug, or a combination of drugs, before exposure to HIV, with the hope that it would lower their risk of infection PrEP is still experimental and has not yet been shown to work in humans What is PrEP?

  3. PrEP Agents in Effectiveness Trials • Oral PrEP • tenofovir disoproxil fumarate -TDF Brand name: Viread • tenofovir plus emtricitabine – TDF/FTC Brand name: Truvada • Topical PrEP • tenofovir gel

  4. Current Ideas on How PrEP Could be Used • Oral: daily • Oral: intermittently • Topical: gel • Topical: vaginal ring, other formulations • Injection, long-term acting methods

  5. Concerns about PrEP • Long-term drug for healthy people: different risk benefit ratio • Potential for side effects and toxicity over time • Potential for resistance: current agents being studied are used for HIV treatment • Adherence for healthy people • HIV testing would be required for PrEP access and on an ongoing basis • With limited resources for HIV treatment, is it appropriate to use ARVs for prevention? • Delivery in resource limited settings

  6. The PrEP Pipeline • Oral: largely based on tenofovir • Topical: robust pipeline with many compounds being considered • Injectable: TMC 278LA

  7. Thank you!

More Related